Skip to main content

Table 3 Clinicopathologic characteristics of DDLPS (whole section) and UPS (TMA)

From: Status of programmed death-ligand 1 expression in sarcomas

  DDLPS, whole section UPS, TMA
Total Negative Positive P Total Negative Positive P
N 32 25 7   60 48 12  
Age, year (median) 56 55 58 0.616 53 55 42.5 0.132
M:F 19:13 15:10 4:3 > 0.99 32:28 28:20 4:8 0.121
Chemotherapy, n (%) 6/32 (18.8%) 5/25 (20.0%) 1/7 (14.3%) > 0.99 27/60 (45.0%) 21/48 (43.8%) 6/12 (50%) 0.754
Radiation therapy, n (%) 20/32 (62.5%) 15/25 (60.0%) 5/7 (71.4%) 0.683 30/60 (50%) 22/48 (45.8%) 8/12 (66.7%) 0.197
Recurrence, n (%) 11/32 (34.4%) 8/25 (32.0%) 3/7 (42.9%)   27/60 (45.0%) 22/48 (45.8%) 5/12 (41.7%)  
Expire, n (%) 3/32 (9.4%) 1/25 (4.0%) 2/7 (28.6%)   36/60 (60.0%) 29/48 (60.4%) 7/12 (58.3%)  
Tumor size (cm, median) 12.75 12.5 14 0.569 6 5.35 7 0.523
Resection margin involved, n (%) 28/32 (87.5%) 22/25 (88.0%) 6/7 (85.7%) > 0.99 25/49 (51.0%) 21/39 (53.8%) 4/10 (40.0%) 0.496
FNCLCC         
2 28/32 (87.5%) 23/25 (92.0%) 5/7 (71.4%) 0.201 17/41 (41.5%) 14/33 (42.4%) 3/8 (37.5%) > 0.99
3 4/32 (12.5%) 2/25 (8.0%) 2/7 (28.6%)   24/41 (58.5%) 19/33 (57.6%) 5/8 (62.5%)  
  1. Negative, no PD-L1 immunoreactivity; positive, ≥ 1% PD-L1 immunoreactivity
  2. DDLPS dedifferentiated liposarcoma, UPS undifferentiated liposarcoma, RFS recurrence free survival